.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
UBS
McKesson
Express Scripts
Cerilliant
QuintilesIMS
Colorcon
McKinsey
Harvard Business School
Julphar

Generated: September 25, 2017

DrugPatentWatch Database Preview

BEPREVE Drug Profile

« Back to Dashboard

What is the patent landscape for Bepreve, and when can generic versions of Bepreve launch?

Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in sixteen countries.

The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.

Summary for Tradename: BEPREVE

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list74
Clinical Trials: see list5
Patent Applications: see list15
Drug Prices:see details
DailyMed Link:BEPREVE at DailyMed

Pharmacology for Tradename: BEPREVE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc
BEPREVE
bepotastine besilate
SOLUTION/DROPS;OPHTHALMIC022288-001Sep 8, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb Inc
BEPREVE
bepotastine besilate
SOLUTION/DROPS;OPHTHALMIC022288-001Sep 8, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bausch And Lomb Inc
BEPREVE
bepotastine besilate
SOLUTION/DROPS;OPHTHALMIC022288-001Sep 8, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for BEPREVE

Drugname Dosage Strength RLD Submissiondate
bepotastine besilateOphthalmic Solution1.5%Bepreve9/9/2013

Non-Orange Book Patents for Tradename: BEPREVE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,307,052 Acid-addition salts of optically active piperidine compound and process for producing the same► Subscribe
8,883,825Aqueous liquid preparations and light-stabilized aqueous liquid preparations► Subscribe
7,282,589Acid addition salt of optically active piperidine compound and process for preparing the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BEPREVE

Country Document Number Estimated Expiration
Japan2014012732► Subscribe
Japan2014169294► Subscribe
Germany69712784► Subscribe
Austria528003► Subscribe
Japan5360605► Subscribe
Japan2016006059► Subscribe
Japan3631748► Subscribe
Japan4562229► Subscribe
Japan3157118► Subscribe
Portugal949260► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Merck
Baxter
US Army
Citi
Johnson and Johnson
Fish and Richardson
Queensland Health
Healthtrust
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot